Terminated PHASE2 INTERVENTIONAL 3-arm NCT01508000

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (BOS2)

Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS/NRAS Colorectal Cancer

Sponsor: Amgen

Conditions Colorectal Cancer Metastatic KRAS Wild Type Colorectal Cancer Liver Metastases

Interventions Bevacizumab FOLFOX6 Panitumumab Surgery

Updated 6 times since 2017 Last updated: Oct 11, 2016 Started: Jun 30, 2013 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low or poor accrual

Other terminated trials from Amgen

See all terminations from Amgen

Other Colorectal Cancer Metastatic trials with similar outcome

Browse all Colorectal Cancer Metastatic trials

Listed as NCT01508000, this PHASE2 trial focuses on Colorectal Cancer Metastatic and KRAS Wild Type Colorectal Cancer and remains terminated or withdrawn. Sponsored by Amgen, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
European Organisation for Research and Treatment of Cancer - EORTC
Roche Pharma AG

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Avignon, France , Barcelona, Spain , Bordeaux, France , Boulogne-Billancourt, France , Brussels, Belgium , Geneva, Switzerland , Ghent, Belgium , Kortrijk, Belgium , Le Kremlin-Bicêtre, France and 12 more locations